The anti-EGFR x anti-CD3 LiTE specifically activates and redirects polyclonal mouse T cells to kill EGFR-positive cancer cells, while the Albu-LiTCo combines PD-L1/PD-1 axis blockade with PD-L1-dependent 4-1BB costimulation and enhances EGFR-specific LiTE T cell-mediated activation in vitro. Here, EGFR is linked to cancer.